PL217858B1 - Fragment apolipoproteiny B lub jego miejsce aktywne, zawierająca go kompozycja farmaceutyczna i szczepionka, zastosowanie tego fragmentu, szczepionka zawierająca przeciwciało przeciwko temu fragmentowi, sposób diagnozowania in vitro oraz zastosowanie tego przeciwciała - Google Patents

Fragment apolipoproteiny B lub jego miejsce aktywne, zawierająca go kompozycja farmaceutyczna i szczepionka, zastosowanie tego fragmentu, szczepionka zawierająca przeciwciało przeciwko temu fragmentowi, sposób diagnozowania in vitro oraz zastosowanie tego przeciwciała

Info

Publication number
PL217858B1
PL217858B1 PL391615A PL39161502A PL217858B1 PL 217858 B1 PL217858 B1 PL 217858B1 PL 391615 A PL391615 A PL 391615A PL 39161502 A PL39161502 A PL 39161502A PL 217858 B1 PL217858 B1 PL 217858B1
Authority
PL
Poland
Prior art keywords
fragment
peptide
mda
antibodies
antibody
Prior art date
Application number
PL391615A
Other languages
English (en)
Polish (pl)
Inventor
Jan Nilsson
Shan Prediman K
Original Assignee
Cedars Sinai Medical Center
Forskarpatent I Syd Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0101232A external-priority patent/SE0101232D0/xx
Application filed by Cedars Sinai Medical Center, Forskarpatent I Syd Ab filed Critical Cedars Sinai Medical Center
Publication of PL217858B1 publication Critical patent/PL217858B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
PL391615A 2001-04-05 2002-04-05 Fragment apolipoproteiny B lub jego miejsce aktywne, zawierająca go kompozycja farmaceutyczna i szczepionka, zastosowanie tego fragmentu, szczepionka zawierająca przeciwciało przeciwko temu fragmentowi, sposób diagnozowania in vitro oraz zastosowanie tego przeciwciała PL217858B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0101232A SE0101232D0 (sv) 2001-04-05 2001-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based elisa for determination of immune responses against oxidized low density liprotein
SE0103754A SE0103754L (sv) 2001-04-05 2001-11-09 Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid

Publications (1)

Publication Number Publication Date
PL217858B1 true PL217858B1 (pl) 2014-08-29

Family

ID=26655437

Family Applications (4)

Application Number Title Priority Date Filing Date
PL391615A PL217858B1 (pl) 2001-04-05 2002-04-05 Fragment apolipoproteiny B lub jego miejsce aktywne, zawierająca go kompozycja farmaceutyczna i szczepionka, zastosowanie tego fragmentu, szczepionka zawierająca przeciwciało przeciwko temu fragmentowi, sposób diagnozowania in vitro oraz zastosowanie tego przeciwciała
PL02367301A PL367301A1 (en) 2001-04-05 2002-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
PL400308A PL400308A1 (pl) 2001-04-05 2002-04-05 Terapia immunizacyjna w oparciu o peptydy do leczenia miazdzycy oraz w oparciu o peptydy do okreslania odpowiedzi odpornosci przeciwko utlenionym lipoproteinom o niskiej gestosci
PL385189A PL215401B1 (pl) 2001-04-05 2002-04-05 Fragment apolipoproteiny B lub jego miejsce aktywne, zawierajaca go kompozycja farmaceutyczna i szczepionka, zastosowanie tego fragmentu , szczepionka zawierajaca przeciwcialo przeciwko temu fragmentowi, sposób diagnozowania in vitro oraz zastosowanie tego przeciwciala

Family Applications After (3)

Application Number Title Priority Date Filing Date
PL02367301A PL367301A1 (en) 2001-04-05 2002-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
PL400308A PL400308A1 (pl) 2001-04-05 2002-04-05 Terapia immunizacyjna w oparciu o peptydy do leczenia miazdzycy oraz w oparciu o peptydy do okreslania odpowiedzi odpornosci przeciwko utlenionym lipoproteinom o niskiej gestosci
PL385189A PL215401B1 (pl) 2001-04-05 2002-04-05 Fragment apolipoproteiny B lub jego miejsce aktywne, zawierajaca go kompozycja farmaceutyczna i szczepionka, zastosowanie tego fragmentu , szczepionka zawierajaca przeciwcialo przeciwko temu fragmentowi, sposób diagnozowania in vitro oraz zastosowanie tego przeciwciala

Country Status (18)

Country Link
EP (42) EP2305708A1 (https=)
JP (6) JP2004529143A (https=)
CN (4) CN101284874B (https=)
AT (2) ATE415423T1 (https=)
AU (1) AU2002246484B8 (https=)
BR (1) BR0208685A (https=)
CA (3) CA2443223C (https=)
CY (1) CY1108817T1 (https=)
DE (1) DE60230029D1 (https=)
DK (3) DK1383526T3 (https=)
EE (2) EE200300487A (https=)
ES (2) ES2317999T3 (https=)
IL (4) IL158285A0 (https=)
PL (4) PL217858B1 (https=)
PT (1) PT1383526E (https=)
RU (1) RU2296582C2 (https=)
SE (1) SE0103754L (https=)
WO (1) WO2002080954A1 (https=)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
PL372925A1 (en) 2001-09-28 2005-08-08 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
AU2003267905B2 (en) * 2002-10-04 2009-02-05 Biolnvent International Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302422D0 (sv) * 2003-09-11 2003-09-11 Forskarpatent I Syd Ab Peptide-based immunization therapy for treatment of atherosclerosis
SE0400683D0 (sv) 2004-03-19 2004-03-19 Forskarpatent I Syd Ab Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis
JP2007531537A (ja) 2004-04-06 2007-11-08 セダーズ−シナイ　メディカル　センター アポリポタンパク質ａ−ｉおよびアポリポタンパク質ａ−ｉｍｉｌａｎｏをコードする組換えアデノ随伴ウイルスベクターによる血管疾患の予防および処置
ATE463254T1 (de) * 2004-04-15 2010-04-15 Athera Biotechnologies Ab Antikörper gegen phosphorylcholinkonjugate
EP1676602A1 (en) * 2005-01-04 2006-07-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Continuous administration of epitopes derived from protein present in atherosclerotic plaque for the treatment of atherosclerosis
GB0517878D0 (en) 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
CA2669863A1 (en) * 2006-12-22 2008-07-03 Abbott Laboratories Cardiovascular autoimmune disease panel and methods of using same
WO2008104194A1 (en) * 2007-02-28 2008-09-04 Bioinvent International Ab Oxidized ldl and antibodies thereto for the treatment of atheroscleroti c plaques
CA2681162C (en) 2007-03-15 2015-11-24 Novartis Ag Benzyl and pyridine derivatives as modulators of hedgehog pathway
ES2897492T3 (es) * 2007-11-05 2022-03-01 Nordic Bioscience Imaging As Marcadores bioquímicos para la evaluación de riesgos de CVD
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
JP5742002B2 (ja) * 2008-08-15 2015-07-01 藤倉化成株式会社 動脈硬化診断用ポリペプチドマーカー、及び該マーカー等を用いる動脈硬化の検出を補助する方法、並びに動脈硬化診断用キット
WO2011060329A1 (en) 2009-11-14 2011-05-19 Kuang-Yuh Chyu Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
US8506964B2 (en) 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
US20130142760A1 (en) 2010-08-18 2013-06-06 Cedars-Sinai Medical Center Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer
RU2013126626A (ru) * 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер Иммуномодулирующие способы и системы для лечения и/или предотвращения гипертензий
CN103501806A (zh) * 2010-11-12 2014-01-08 赛达斯西奈医疗中心 用于治疗和/或预防动脉瘤的免疫调节方法和系统
EP2637686A2 (en) 2010-11-12 2013-09-18 Cedars-Sinai Medical Center Immunomodulatory compositions, methods and systems comprising immunogenic fragments of apob100
HUE045163T2 (hu) 2011-08-09 2019-12-30 Athera Biotechnologies Ab Új ellenanyagok foszforilkolin ellen
CN103906532B (zh) 2011-08-09 2018-01-26 阿瑟拉生物技术公司 结合磷酰胆碱（pc）和/或pc结合物的抗体
RU2495048C1 (ru) * 2012-04-18 2013-10-10 Андрей Валентинович Исаев Пептид, обладающий антиатеросклеротическим действием и композиция для профилактики и лечения атеросклероза сосудов
ES2859559T3 (es) * 2012-11-06 2021-10-04 Les Hopitaux Univ De Geneve Péptidos miméticos
CN103520713B (zh) * 2013-10-16 2015-10-28 西北农林科技大学 一种ApoB100酵母重组疫苗及其制备方法和应用
CN103860470A (zh) * 2014-03-05 2014-06-18 贵州中泰生物科技有限公司 一种口服高密度脂蛋白脂质体的制备方法
CN105315364B (zh) * 2014-06-17 2018-09-18 广州文瑞生物科技有限公司 胶原蛋白vi疫苗预防动脉粥样硬化
CN114085283A (zh) 2015-05-19 2022-02-25 拉·约拉过敏反应及免疫医学研究所 调节炎症应答及治疗不良心血管事件、病和粥样硬化的人apob100表位、方法和用途
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
CN108478817B (zh) * 2018-03-16 2020-10-27 北京大学 一种动脉粥样硬化检测试剂及其制备方法
JP7357646B2 (ja) 2018-05-29 2023-10-06 アブセントラ，エルエルシー 乾癬の治療のための組成物及び方法
WO2019232081A1 (en) 2018-05-29 2019-12-05 Abcentra, Llc Compositions and methods for treatment of rheumatoid arthritis and accelerated atherosclerosis
CN115025210B (zh) * 2021-03-05 2025-09-05 香港中文大学 减少动脉粥样硬化进展的肽疫苗组合物和药物制剂
CN115025211A (zh) * 2021-11-02 2022-09-09 南京理工大学 用于动脉粥样硬化治疗的纳米疫苗及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970144A (en) 1984-12-31 1990-11-13 International Genetic Engineering Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
US5972890A (en) 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
WO1993018067A1 (en) * 1992-03-06 1993-09-16 Abbott Laboratories Immunocapture assay for direct quantitation of specific lipoprotein cholesterol levels
WO1994000592A1 (en) * 1992-06-26 1994-01-06 Exocell, Inc. Monoclonal antibodies against glycated low density lipoprotein
EP0671926B1 (en) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunomodulatory peptides
KR0185334B1 (ko) 1995-11-02 1999-04-01 김은영 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이
GB9609702D0 (en) * 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
GB9620153D0 (en) * 1996-09-27 1996-11-13 Univ Strathclyde Non-naturally occurring lipoprotein particle
GB9705831D0 (en) * 1997-03-20 1997-05-07 Univ Leicester Oxidised ldl
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
US6225070B1 (en) * 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US6156315A (en) * 1997-10-10 2000-12-05 The Trustees Of Columbia University In The City Of New York Method for inhibiting the binding of low density lipoprotein to blood vessel matrix
EP0911344B1 (en) * 1997-10-15 2004-03-03 Fujirebio Inc. Anti-Apo-B-48 monoclonal antibody, hybridoma, and methods of use
EP1062512A4 (en) * 1998-03-10 2001-12-12 Univ California METHODS AND TOOLS USED TO IDENTIFY COMPOUNDS THAT MODULATE ATHEROSCLEROSIS BY ALTERATION OF THE LDL-PROTEOGLYCANE BINDING
AU5200699A (en) * 1998-07-13 2000-02-01 University Of Otago Inhibition of lipoprotein formation
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
JP2003513027A (ja) * 1999-10-26 2003-04-08 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア アテローム性動脈硬化症の診断、結像、治療用の薬剤及びその方法
AU3087801A (en) * 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
MXPA02008616A (es) * 2000-03-03 2003-02-24 Smithkline Beecham Biolog Vacuna para el tratamiento de la arterosclerosis.
SE0000855D0 (sv) * 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
GB0017641D0 (en) * 2000-07-18 2000-09-06 Medigene Oy Peptides and their use
EP1186299A1 (en) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
EP1592445A4 (en) * 2000-10-25 2007-01-10 Vincent Agnello METHOD FOR INHIBITING HEPATITIS C VIRUS (HCV) INFECTION AND OTHER FLAVIRIDAE / I FAMILY VIRUSES, AND OTHER BLOODY-VIRUSES COMPLEXING WITH LOW OR VERY LOW DENSITY LIPOPROTEIN DENSITY, BY PREVENTING VIRAL ENTRY IN A CELL
AU2002241603A1 (en) * 2000-11-10 2002-06-03 University Of Utah Research Foundation Carrier system for specific artery wall gene delivery
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
KR20030097854A (ko) * 2001-05-15 2003-12-31 저팬 이뮤너리서치 래버래터리스 컴퍼니 리미티드 고밀도 리포단백질 반응성 펩티드
JP2005504025A (ja) * 2001-07-20 2005-02-10 アイトゲネシシェ テクニシェ ホッヒシュル チューリッヒ（エーテーハーツェット） スルフォネート化またはスルフェート化アミノ酸から誘導された生物学的薬剤の使用法と組成物

Also Published As

Publication number Publication date
JP2011068654A (ja) 2011-04-07
EP1383526B1 (en) 2008-11-26
ATE415423T1 (de) 2008-12-15
JP5300819B2 (ja) 2013-09-25
EP2289924A1 (en) 2011-03-02
PL367301A1 (en) 2005-02-21
EP1383526A1 (en) 2004-01-28
JP5270456B2 (ja) 2013-08-21
DE60230029D1 (de) 2009-01-08
EP2289931A1 (en) 2011-03-02
CN1505525B (zh) 2012-11-07
EP2295461A1 (en) 2011-03-16
RU2296582C2 (ru) 2007-04-10
EP2147930A2 (en) 2010-01-27
CN103122031B (zh) 2015-07-22
EP2289913A1 (en) 2011-03-02
AU2002246484B2 (en) 2007-04-19
EP2289920A1 (en) 2011-03-02
DK2006301T3 (da) 2011-09-12
JP2013144687A (ja) 2013-07-25
CN101486766A (zh) 2009-07-22
EP2289934A1 (en) 2011-03-02
EP2289928A1 (en) 2011-03-02
SE0103754L (sv) 2002-10-06
EP2289912A1 (en) 2011-03-02
EP2289929A1 (en) 2011-03-02
EP2289933A1 (en) 2011-03-02
EP2295464A1 (en) 2011-03-16
EP2289923A1 (en) 2011-03-02
EP2289930A1 (en) 2011-03-02
DK1383526T3 (da) 2009-03-30
EP2295464B1 (en) 2015-06-03
JP2011063598A (ja) 2011-03-31
IL158285A0 (en) 2004-05-12
DK2295464T3 (en) 2015-08-17
PL400308A1 (pl) 2012-12-17
AU2002246484B8 (en) 2007-06-14
EP2295457A1 (en) 2011-03-16
EP2305706A1 (en) 2011-04-06
ES2317999T3 (es) 2009-05-01
EP2289914A1 (en) 2011-03-02
CA2606839A1 (en) 2002-10-17
EP2006301B1 (en) 2011-05-25
EP2305707A1 (en) 2011-04-06
JP5300820B2 (ja) 2013-09-25
EP2289927A1 (en) 2011-03-02
IL158285A (en) 2009-12-24
EP2295463A1 (en) 2011-03-16
CA2443223A1 (en) 2002-10-17
CY1108817T1 (el) 2014-04-09
RU2003132443A (ru) 2005-02-27
EE200300487A (et) 2004-02-16
EP2289919A1 (en) 2011-03-02
EP2289932A1 (en) 2011-03-02
BR0208685A (pt) 2004-03-30
EP2289915A1 (en) 2011-03-02
EP2147929A3 (en) 2010-04-14
EP2147928A3 (en) 2010-04-14
CN101284874B (zh) 2012-10-03
JP2009191078A (ja) 2009-08-27
CN101284874A (zh) 2008-10-15
JP5613890B2 (ja) 2014-10-29
EP2289922A1 (en) 2011-03-02
EP2295459A1 (en) 2011-03-16
JP2004529143A (ja) 2004-09-24
EP2289926A1 (en) 2011-03-02
EP2295458A1 (en) 2011-03-16
EP2289921A1 (en) 2011-03-02
EP2289918A1 (en) 2011-03-02
EP2295460A1 (en) 2011-03-16
EP2289925A1 (en) 2011-03-02
IL195356A0 (en) 2009-08-03
PL215401B1 (pl) 2013-12-31
ES2546293T3 (es) 2015-09-22
EP1918300A2 (en) 2008-05-07
EP2147680A2 (en) 2010-01-27
CN103122031A (zh) 2013-05-29
JP2008169215A (ja) 2008-07-24
EP2147930A3 (en) 2010-04-14
ATE510851T1 (de) 2011-06-15
EP2289917A1 (en) 2011-03-02
CA2443223C (en) 2013-11-26
EP2147680A3 (en) 2010-04-14
PT1383526E (pt) 2009-02-27
AU2002246484A1 (en) 2002-10-21
EP2305708A1 (en) 2011-04-06
EP2295460B1 (en) 2015-06-03
CA2606839C (en) 2015-06-09
EE200700052A (et) 2008-08-15
CN1505525A (zh) 2004-06-16
EP2147928A2 (en) 2010-01-27
EP2289935A1 (en) 2011-03-02
WO2002080954A1 (en) 2002-10-17
EP1918300A3 (en) 2009-06-17
EP2006301A1 (en) 2008-12-24
IL188286A0 (en) 2008-03-20
EP2295462A1 (en) 2011-03-16
CA2827167A1 (en) 2002-10-17
SE0103754D0 (sv) 2001-11-09
EP2147929A2 (en) 2010-01-27
EP2289916A1 (en) 2011-03-02
EP2289934B1 (en) 2013-11-13

Similar Documents

Publication Publication Date Title
CN101284874B (zh) 以肽为基础的治疗动脉粥样硬化的免疫疗法
US7544360B2 (en) Peptide epitopes of apolipoprotein B